Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: A report from the CORONOR investigators

Delsart, Pascal; Lemesle, Gilles; Lamblin, Nicolas; Tricot, Olivier; Meurice, Thibaud; Mycinski, C; Elkohen, Mariam; Chmaït, Akram; Haulon, Stéphan; Bauters, Christophe

doi:10.1177/2047487314538857

Cited by 8 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21,22 Thus, in relation to previous studies, our study mainly focused on all-cause death and drew a conclusion for this "hard endpoint" in MI patients. Comparing our results to the studies where the study populations was stable post-MI patients, CORONO study conducted by Delsart P et al showed that the rate of all-cause death for their stable CAD patients without coronary vascular intervention history was around 5.5% at 1 year, 23 which was higher than the corresponding rate in our 18-month DAPT group (3.7%) and similar to the rate in our 12-month DAPT group (5.9%). The baseline rate of DAPT use for their non-coronary vascular intervention patients was 20%, and angiotensin system antagonists, beta-blockers and statins were widely prescribed in these patients.…”

Section: Discussionsupporting

confidence: 62%

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients without Revascularization: Results from a China Acute Myocardial Infarction (CAMI) registry study

Huang,

Yang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: At least 12-month dual antiplatelet therapy (DAPT) is one of the standards of care following Percutaneous Coronary Intervention (PCI) in patients with acute coronary syndrome. However, study on prolonged DAPT for acute myocardial infarction (AMI) patients without revascularization is limited. Methods: We studied 1744 AMI patients without revascularization from the China Acute Myocardial Infarction registry between January 2013 and September 2014. These patients were on DAPT and did not experience AMI, stroke, or bleeding events at 12-month follow-up. We divided them into two groups: 12-month DAPT group (DAPT for at least 12 months but less than 18 months) and 18-month DAPT group (DAPT for at least 18 months). The primary outcome is 24-month all-cause death. Results: Overall, 1221 (70.0%) patients took DAPT for ?12 months but <18 months, while 523 (30.0%) patients took DAPT for ?18 months. The two groups had comparable proportions with high ischemic risk (27.0% vs. 25.6%, P = 0.5418), as well as high bleeding risk (29.0% vs. 28.5%, P = 0.8316). At 24 months, the all-cause mortality rate of 18-month DAPT group was significantly lower than that for 12-month DAPT group (3.7% vs 5.9%, P = 0.0471). Adjusted hazard ratio for all-cause death also showed statistical significance (0.59, 95% CI: 0.35-0.99, P = 0.0444). Conclusions: DAPT for at least 18 months was associated with lower 24-month mortality for non-revascularization AMI patients without events within 12 months after onset.

show abstract

Section: Discussionsupporting

confidence: 62%

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients without Revascularization: Results from a China Acute Myocardial Infarction (CAMI) registry study

Huang,

Yang,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Indeed, it is today well recognized that CAD patients who present markers of diffuse atherosclerosis are at higher risk as compared with patients with focal disease [4][5][6][7][8][9][10][11][12][13][14][15][16]32,35,36]. As a perfect illustration of this, patients with high-SYNTAX score have shown to experience poor outcome after PCI [24][25][26][27].…”

Section: Long Lesion/stent As a Marker Of Diffuse Atherosclerosis And Hmentioning

confidence: 99%

Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy

Schurtz¹,

Manchuelle²,

Lemesle³

2015

Interventional Cardiology

Self Cite

View full text Add to dashboard Cite

“…10,11 Segundo diretrizes internacionais de prevenção secundária das DCV, recomenda-se tratamento medicamentoso ao longo da vida com antiagregantes plaquetários, betabloqueadores, estatinas e inibidores da enzima conversora de angiotensina (IECA). [11][12][13][14] Com o aumento do uso desse tratamento para prevenção secundária, a cada 10.000 pacientes, mais de 104 vidas poderiam ser salvas e 191 eventos isquêmicos recorrentes poderiam ser evitados se a maioria desses pacientes com doenças crônicas fossem tratados na Atenção Primária. A dinâmica proposta pela Estratégia Saúde da Família (ESF), centrada na promoção da qualidade de vida e intervenção dos fatores que a colocam em risco, permite a identificação mais acurada e um melhor acompanhamento dos indivíduos com vistas à prevenção de doenças, principalmente as cardiovasculares, tendo um impacto sobre as taxas de incidência das mesmas.…”

Section: Introductionunclassified

Prevenção secundária farmacológica de doenças cardiovasculares em população rural assistida por unidades básicas de saúde do município de Embu-Guaçu/SP

Dias¹,

Juliano²,

França³

et al. 2021

Rev. Atenção Saúde

View full text Add to dashboard Cite

Introdução: A prevenção secundária das doenças cardiovasculares, incluindo farmacoterapia, é importante não apenas para diminuir a morbidade e mortalidade das doenças cardiovasculares (DCV), mas também porque tem impacto na qualidade de vida. Objetivos: O objetivo desse trabalho foi avaliar a prevenção secundária medicamentosa em pacientes que apresentaram eventos cardiovasculares, frequentadores das Unidades saúde da família do município de Embu-Guaçu. Casuística e Métodos: Foi realizado um estudo observacional e transversal, com 68 pacientes que apresentaram pelo menos um evento cardiovascular e que responderam a um questionário contemplando dados sócio demográficos, identificação do evento cardiovascular, medicações prescritas, prescritores e o local de acompanhamento. Resultados: Dentre os eventos cardiovasculares, o Acidente Vascular Encefálico - AVE foi o mais prevalente (p< 0,0001) seguido de Infarto Agudo do Miocárdio - IAM. Apenas 21% das prescrições estavam adequadas; em sua grande maioria, os participantes eram acompanhados pelo cardiologista. Dos pacientes acompanhados pela atenção primária à saúde, apenas 26% estavam com a prescrição adequada. Conclusões: A prevenção secundária medicamentosa dos pacientes estudados nessas UBS no município de Embu-Guaçu está longe de ser considerada ideal, pois apenas 26% dessas prescrições encontram-se adequadas segundo as diretrizes sobre prevenção secundária medicamentosa das DCV, e aquém de alguns estudos que chegam a ser 90%.

show abstract

Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: A report from the CORONOR investigators

Cited by 8 publications

References 19 publications

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients without Revascularization: Results from a China Acute Myocardial Infarction (CAMI) registry study

Prolonged Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients without Revascularization: Results from a China Acute Myocardial Infarction (CAMI) registry study

Stent length as a potential indicator to select patients who may benefit from long-term dual antiplatelet therapy

Prevenção secundária farmacológica de doenças cardiovasculares em população rural assistida por unidades básicas de saúde do município de Embu-Guaçu/SP

Contact Info

Product

Resources

About